1. Electronics retailer Currys increases profit guidance Adjusted profit before tax for the current year is expected to be at least £115...
What it does Faron Pharmaceuticals Oy (LON:FARN)(NASDAQFIRSTNORTH:FARON) is a Finnish drug...
Rolls-Royce Holdings PLC (LSE:RR.), easyJet PLC and Tesco PLC (LSE:TSCO) have received backing...
Faron Pharmaceuticals Limited (AIM:FARN) will release updated results from its BEXMAB clinical...
AstraZeneca PLC (LSE:AZN)’s £780 million takeover of France-based Amolyt Pharma on Thursday...
Faron Pharmaceuticals Limited (AIM:FARN) chief executive Dr Markku Jalkanen joins Proactive's Stephen Gunnion with additional positive data from the Phase 1 study of the ongoing bexmarilimab (BEXMAB) trial that has moved into Phase 2 for higher-risk (HR) myelodysplastic syndrome (MDS) patients...